Abstract:Major depressive disorder is one of the primary causes of disability and disease worldwide. The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas. The recent approval of esketamine as a rapid-acting antidepressant drug in treatment-resistant depression, has definitively projected glutamatergic transmission as a key constituent in the use of new drugs in antidepressant therapy. In this review we have examined the role of several brain areas: namely, the hippocampus, the medial Prefrontal Cortex (mPFC), the nucleus accumbens (NAc), the Lateral Habenula (LHb), the amygdala and the Bed Nucleus of Stria Terminalis (BNST). The reason for undertaking an in-depth review is due to their significant role in animal models of depression, which highlight their inter-connections as well as their inputs and outputs. In particular, we examined the modification of the expression and release of the brain derived neurotrophic factor (BDNF) and associated changes in dendritic density induced by chronic stress in the above areas of animal models of depression (AnMD). We also examined the effectiveness of ketamine and standard antidepressants in reversing these alterations, with the aim of identifying a brain circuit where pathological alteration might trigger the appearance of depression symptoms. Based on the role that these brain areas play in the generation of the symptoms of depression, we assumed that the mPFC, the NAc/Ventral Tegmental Area (VTA) and the hippocampus form a primary circuit of depression, where regular performance can endure resilience to stress. We have also examined how this circuit is affected by environmental challenges and how the activation of one or more areas, including amygdala, LHb or BNST can produce local detrimental effects that spread over specific circuits and generate depression symptoms. Furthermore, we also examined how, through their outputs, these three areas can negatively influence the NAc/VTA-PFC circuit directly or through the BNST, to generate anhedonia, one of the most devastating symptoms of depression.

Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review)

Neuroplasticity: Pathophysiology and Role in Major Depressive Disorder

5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology

Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression

Changes in Hippocampal Plasticity in Depression and Therapeutic Approaches Influencing These Changes

Neuroplasticity and the Biological Role of Brain Derived Neurotrophic Factor in the Pathophysiology and Management of Depression

Structural neural plasticity evoked by rapid-acting antidepressant interventions

[Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders]

Repurposing Ketamine in the Therapy of Depression and Depression-Related Disorders: Recent Advances and Future Potential

Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

Novel Insights Into the Neurobiology of the Antidepressant Response From Ketamine Research: A Mini Review

New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity

Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants

Role of BDNF in the pathophysiology and treatment of depression: Activity‐dependent effects distinguish rapid‐acting antidepressants

Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies

Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder

A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists